Printer Friendly
The Free Library
19,585,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BioSphere Medical to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference.


ROCKLAND, Mass. -- BioSphere Medical, Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: BSMD), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids Uterine Fibroids Definition

Uterine fibroids (also called leiomyomas or myomas) are benign growths of the muscle inside the uterus. They are not cancerous, nor are they related to cancer.
, hypervascularized tumors and vascular malformations, announced today that Richard Faleschini, President and Chief Executive Officer, is scheduled to present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Wednesday, November 7, 2007 at 10:30 am Eastern Time. The event is taking place at the New York Palace
  • Palace Theatre, New York
  • New York Palace, Budapest, Hungary
 hotel.

The presentation will be broadcast live over the Internet via the "Investors" page of the BioSphere Medical website at www.biospheremed.com or at http://www.wsw.com/webcast/rrshq12/bsmd. To listen to the live event, go to the website at least 15 minutes early to register, download and install any necessary audio software. A replay of the webcast will be available at the Company's website for 90 days following the presentation.

About BioSphere Medical, Inc.

BioSphere Medical, Inc., a medical device company based in Rockland, Massachusetts, seeks to pioneer and commercialize minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered microsphere Not to be confused with Glass microphere.
This article largely refers to micropheres or protein protocells as small spherical units postulated by some scientists as a key stage in the origin of life.
 technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties for a variety of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization Uterine Fibroid Embolization Definition

Uterine fibroids are growths in the muscular tissue of the womb (uterus). Uterine fibroid embolization is non-surgical removal of the growths through the use of a tubular device called a catheter.
, or UFE UFE Uterine Fibroid Embolization
UFE United for a Fair Economy
UFE Ufficio Federale dell'Energia
UFE Uniform Final Examination
UFE Urban Challenge Final Event (DARPA)
UFE Unidentified Flags and Ensigns
UFE Unrestricted Free Agent
. The Company's products continue to gain acceptance in this rapidly emerging procedure as well as in a number of other new and established medical treatments.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. For a discussion of important risks and uncertainties which could cause actual results to differ from those contained in such forward-looking statements, see "Risk Factors" in BioSphere's Quarterly Report on Form 10-Q Form 10-Q

See 10-Q.
 for the quarter ended June 30, 2007, as filed by the Company with the Securities and Exchange Commission, and described in other filings made by the Company from time to time with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date of this press release and the Company disclaims any obligation to update these forward-looking statements as a result of changed events, circumstances or otherwise.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Conference news
Date:Oct 29, 2007
Words:374
Previous Article:Emergent BioSolutions to Present at November Investor Conferences.
Next Article:Lithography Steppers and Scanners Market to Receive Boost from Product Innovation with Improved Productivity.
Topics:



Related Articles
NitroMed to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference.
Dyax Corp. To Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference.
Avalon Pharmaceuticals to Present at Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference.
Rexahn Pharmaceuticals, Inc. to Present at the Acumen BioFin 9th Annual Healthcare Conference.
Tercica to Present at November Investment Conferences.
Depomed to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference.
Genitope Corporation to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference.
AVEO Pharmaceuticals to Present at Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference.
Urigen Pharmaceuticals, Inc. to Present at Acumen BioFin Rodman and Renshaw 9th Annual Healthcare Conference November 6th in New York City.
Columbia Laboratories to Present at Rodman & Renshaw Healthcare Conference in NYC on November 6, 2007.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles